Gil Roth06.12.13
In May, Halo Pharma and Altus Formulation formed a collaboration in which Altus will offer formulation and drug delivery platform expertise and technology to complement Halo's commercial-oriented manufacturing business. We spoke to Halo chief executive officer Clive Bennett about the partnership with Altus. --GYR
Contract Pharma: What does Altus give you that you don't have in-house at Halo?
Clive Bennett: Around 80 to 90% of the clients who come to us know what needs doing. They have a scope of work in mind. In those cases, it's a straightforward process of what we're going to charge for the work and whether we have any suggestions for the process.
That doesn't cover the whole universe. There are some situations, especially in early-stage work, where people have a problem. And there are a variety of those. One current example is the need for abuse-deterrence in opioids. Low solubility is critical for many
Contract Pharma: What does Altus give you that you don't have in-house at Halo?
Clive Bennett: Around 80 to 90% of the clients who come to us know what needs doing. They have a scope of work in mind. In those cases, it's a straightforward process of what we're going to charge for the work and whether we have any suggestions for the process.
That doesn't cover the whole universe. There are some situations, especially in early-stage work, where people have a problem. And there are a variety of those. One current example is the need for abuse-deterrence in opioids. Low solubility is critical for many
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
